The General Hospital Corporation

Dana-farber-cancer Institute Inc.

Canthera Therapeutics Inc.

Sam W Lee

Anna I Mandinova

Victor A Neel

Ruth Sager

Michael Andrew Foley

Zhiqiang Zou

Peter J Elliott

Robert J Gould

Catherine Tomasetto

Catherine Laure Tomasetto

Provided herein are methods and assays for isolating and culturing seborrheic keratosis cells ex vivo. Also provided herein are screening assays using cultured seborrheic keratosis cells and methods for treating seborrheic keratosis in a subject.

Agents and methods for treating and preventing seborrheic keratosis

This disclosure relates to inhibitors of the Wni pathway, and compositions comprising the same, as well as to their use in the treatment of disorders characterized by the activation of Writ pathway signaling (e.g., cancer), as well as to the modulation of cellular events mediated by VVnt pathway signaling.

Wnt/b-catenin inhibitors and methods of use

The invention relates to compounds and composition for the treatment and prevention of cancer. The invention also covers all diseases that may be treated by selective modulation of levels of reactive oxygen species in diseased cells versus normal cells. Methods for the preparation and administration of such compositions are also disclosed. A representative compound according to the invention is: 

Compounds and compositions for treating cancer

The invention provides methods for the treatment of cancer in a subject by the administration of myrsinoic acid A and/or one or more myrsinoic acid A analogs.

Approaches to treat cancer using HB-EGF inhibitors

A method of determining whether a test cell from a given human tissue type is (a) normal, or (b) cancerous or precancerous, by contacting the mRNA of the test cell with a nucleic acid probe which contains a nucleotide sequence at least 15 nucleotides in length which is complementary to a portion of the coding sequence of a candidate tumor suppressor gene, which gene is one that is expressed at a given control level in normal cells of that tissue type; and determining the approximate amount of hybridization of the probe to the mRNA of the test cell, an amount of hybridization one-third or less that seen with the mRNA of a normal cell of that tissue type being an indication that the test cell is cancerous or precancerous. Alternatively, an antibody specific for the candidate tumor suppressor gene product can be substituted for the nucleic acid probe as a means for determining the level of expression of the gene in the test cell. The invention also includes methods of treating a cancerous cell by increasing the level of expression of a candidate tumor suppression gene in the cell; novel candidate tumor suppressor genes; and their use in diagnosis, prognosis, and therapy.

Cancer diagnosis using nucleic acid hybridization

Nucleic acid encoding clone 19 gene product, and protein which interacts specifically with an antibody specific to the gene product of clone 19.

Growing community of inventors

Newton, MA, United States of America

Sam W Lee